Pentagamavunon-0 (PGV-0) Enhance Cytotoxic Effect of Doxorubicin through Increasing of Apoptosis, Senescence and ROS Level on Triple Negative Breast Cancer 4T1

ISCC (Indonesian Journal of Cancer Chemoprevention)

ARTICLE

Ismanurrahman Hadi¹  Riris Istighfari Jenie²  Edy Meiyanto² 

[1]Magister Program of Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada

[2]Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada

[3]Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada

关键词: 4T1;    PGV-0;    Co-chemotherapy;    Cytotoxic;    Senescence;    Apoptosis;    ROS;   

DOI  :  10.14499/indonesianjcanchemoprev11iss1pp7-15

学科分类：药学

来源: Indonesian Society for Cancer Chemoprevention

【 摘 要 】

TNBC, one of the sub type of breast cancers was widely known with high tumorigenic and poor prognosis than others. The development of combination agent (co-chemotherapy) with doxorubicin for chemotherapy of TNBC were carried out to decrease doxorubicin side effect and resistance in cancer. This present study aims to explore the co-chemotherapeutic properties of PGV-0 and investigate induction of doxorubicin on apoptosis, senescence and ROS against TNBC. 4T1 Cell line were used as a TNBC in vitro model. Cytotoxic measurement was performed using MTT assay resulting in IC50 values of 52 μM. Meanwhile, the combination of doxorubicin and PGV-0 showed synergistic effect which decreased cell viability of 4T1 better than single treatment of doxorubicin. Apoptosis analysis was performed using annexin V/PI assay indicated that the combination treatment of PGV-0 and doxorubicin increased apoptosis evidence. Senescence detection was carried out using senescence-associated-β galactosidase (SA-β-gal) assay. The results showed that a single treatment of PGV-0 induced cellular senescence and increased senescence cells in combination treatment. Moreover, DCFDA staining showed that PGV-0 increased ROS level at single treatment, whereas combination treatment increased ROS intracellular compared to the positive control of doxorubicin. Based on these results, PGV-0 has potential as a co-chemotherapeutic candidate on TNBC.

【 授权许可】

CC BY-NC